Aortic rupture

Brain Aneurysm Foundation Announces 2023 Research Grants

Retrieved on: 
Thursday, September 21, 2023
Subarachnoid hemorrhage, Bleeding, Therapy, Beth Israel Deaconess Medical Center, Education, Genetics, Prevalence, Blood, Epigenetics, Impact, Aneurysm, Stroke, Policy, Kick, Aortic rupture, Skull, Research, Risk, Brain, Biomarker, Pop, Science, SAH, ZIC3, BAF, Rupture, Robotics, HDAC2, Big data, Biology, Effectiveness, Diagnosis, Ecosystem, Role, Comparative effectiveness research, Health, Headache, Woman, Social media, Disease, Pharmaceutical industry, Mouse, Engagement

HANOVER, Mass., Sept. 21, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or developing new treatment methods.

Key Points: 
  • Provides Funding for 17 Research Efforts that aim to Address the Underlying Causes of Disease, New Treatment Paradigms and Key Markers of Ruptures and Hemorrhage
    Total Annual Research Funding Eclipses $5 million; BAF Kicks off its Annual Day of Engagement to Support its Mission of Reducing the Prevalence and Impact of Brain Aneurysms
    HANOVER, Mass., Sept. 21, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the recipients of its 2023 research grants, providing support to academic researchers studying the underlying biology of aneurysms or developing new treatment methods.
  • Research grants are a cornerstone of the organization's mission, as it works to fund critical advances at a time where Federal dollars for brain aneurysm research amounts to just over $2 for every person afflicted.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that in some instances can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

With One-in-Fifty People in the US at Risk, the Brain Aneurysm Foundation Launches New Campaign to Increase Disease Awareness and Accelerate Research

Retrieved on: 
Wednesday, September 6, 2023
Survivor, Fibromuscular dysplasia, Marfan syndrome, Beth Israel Deaconess Medical Center, Education, Prevalence, Blood, Stroke, Policy, Aortic rupture, Skull, Research, Brain, Risk, Pop, Pain, Subarachnoid hemorrhage, Polycystic kidney disease, BAF, Rupture, Patient, Physician, Need, Seizure, Nerve, Nausea, Biology, Diagnosis, City, Headache, Woman, Smoking, Death, Family, Memory, Social media, Autosome, Disease, Ehlers–Danlos syndromes, Pharmaceutical industry, Nursing, Aneurysm

HANOVER, Mass., Sept. 6, 2023 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced the launch of "Stop the Pop," a new campaign to increase awareness of the prevalence and impact of the disease and the need for ongoing investment to fund new innovations, screening, and treatment. 

Key Points: 
  • The campaign aims to build awareness of symptoms, genetic and environmental risk factors, and to increase research funding to better understand the underlying causes of the condition and to advance new treatments.
  • "A feeling that something has 'popped' is what we hear most from patients who have experienced a rupture.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that in some instances can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm

Retrieved on: 
Tuesday, March 21, 2023
Technology, Medical Devices, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, Heart, Communication, Abdominal aortic aneurysm, Pulmonary embolism, AAA1, Food and Drug Administration, Aortic rupture, Intelligence, CTA, Multimedia, Risk, TriHealth, Viz, Death, Hospital, Triage, Rupture, AAA, MD, Patient, Physician, Blood, Korea Disease Control and Prevention Agency, Artificial intelligence, AI, FDA, Computed tomography angiography, Food, Disease, Medical device, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).
  • The new artificial intelligence (AI) algorithm and clinical workflow solution will be a part of the VizTM AORTIC Module, an AI solution designed to accelerate treatment decisions for all aortic pathology.
  • An abdominal aortic aneurysm is a bulge in the abdominal aorta, the main artery that carries blood from the heart to the rest of the body.
  • Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals.

Kobe University research: Healthy gut, healthy heart: Gut bacteria and heart disease

Retrieved on: 
Friday, December 9, 2022
Water, Degenerative disease, AAA, Aorta, Ligand, Heart, Spleen, Immune system, Angiotensin, Development, Monocyte, Aortic rupture, Hypertension, Cardiac arrest, Bacteria, NOD1, Patient, Abdominal aortic aneurysm, Internal bleeding, Research, Injection, Cardiovascular disease, Incidence, Kobe University, Death, Bone marrow, AAAS, Tissue, Inflammation, Rupture, Stroke, Swelling, Risk, Pharmaceutical industry, Restaurant, Vaccine, Dietary supplement, Mouse

In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.

Key Points: 
  • In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
  • The composition of bacteria normally residing in the gut is known to play a role in other cardiovascular diseases.
  • The suppression of gut bacteria was, thus, somehow leading to a reduced risk of AAA.
  • This study revealed the link between gut bacteria and the onset of AAA.

Kobe University research: Healthy gut, healthy heart: Gut bacteria and heart disease

Retrieved on: 
Friday, December 9, 2022
Water, Degenerative disease, AAA, Aorta, Ligand, Heart, Spleen, Immune system, Angiotensin, Development, Monocyte, Aortic rupture, Hypertension, Cardiac arrest, Bacteria, NOD1, Patient, Abdominal aortic aneurysm, Internal bleeding, Research, Injection, Cardiovascular disease, Incidence, Kobe University, Death, Bone marrow, AAAS, Tissue, Inflammation, Rupture, Stroke, Swelling, Risk, Pharmaceutical industry, Restaurant, Vaccine, Dietary supplement, Mouse

In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.

Key Points: 
  • In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
  • The composition of bacteria normally residing in the gut is known to play a role in other cardiovascular diseases.
  • The suppression of gut bacteria was, thus, somehow leading to a reduced risk of AAA.
  • This study revealed the link between gut bacteria and the onset of AAA.

Endovascular Aneurysm Repair Global Market Report 2022: Advantages Over Open Heart Surgery Driving Adoption & Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022
Surgery, Health, Other Health, Terumo, Atherosclerosis, Physician, Pulmonary embolism, Anatomy, Growth, CAGR, Degenerative disease, EVAR, Porter's five forces analysis, Research, Medtronic, Aorta, Awareness, Site, AAA, Aortic aneurysm, FDA, Abdominal aortic aneurysm, Benchmarking, Aortic rupture, Pharmaceutical industry, Ridesharing company

Endovascular aneurysm repair (EVAR) is a preferred treatment option for aortic aneurysm, owing to its advantages over open surgery.

Key Points: 
  • Endovascular aneurysm repair (EVAR) is a preferred treatment option for aortic aneurysm, owing to its advantages over open surgery.
  • The endovascular aneurysm repair industry report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the endovascular aneurysm repair market analysis from 2020 to 2030 to identify the prevailing endovascular aneurysm repair market opportunities.
  • In-depth analysis of the endovascular aneurysm repair market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global endovascular aneurysm repair market trends, key players, market segments, application areas, and market growth strategies.

The Abdominal Aortic Aneurysm Market to Boost at a CAGR of 3% During the Study Period (2019-32), Assesses DelveInsight

Retrieved on: 
Monday, May 2, 2022
Aortic rupture, United Kingdom, Stomach, Population, Blood pressure, Abdominal aortic aneurysm, LAS, C1-inhibitor, Aorta, Abdomen, Prevalence, Aneurysm, Patient, Bifurcation, Magnetic resonance angiography, Calcium channel, Cook Group, CT, Human, Incidence, Pressure, Medtronic, Cardinal Health, Anatomy, Spine, Disease, And, AAA, Technology, Growth, Sensation, Tobacco, Shenzhen, Risk, Medical imaging, Cultured pearl, Dairy product

LAS VEGAS, May 2, 2022 /PRNewswire/ -- DelveInsight's Abdominal Aortic Aneurysm Market Insights report includes a comprehensive understanding of current treatment practices, Abdominal Aortic Aneurysm emerging treatment devices, market share of therapy classes, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Points: 
  • The majority of Abdominal Aortic Aneurysm grow slowly without noticeable Abdominal Aortic Aneurysm symptoms.
  • The Abdominal aortic aneurysm ultrasound and Abdominal aortic aneurysm CT scan are among the most commonly used tools for Abdominal aortic aneurysm diagnosis.
  • The Abdominal Aortic Aneurysm Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
    There are currently no Abdominal Aortic Aneurysm drugs available to slow the growth of Abdominal Aortic Aneurysm.
  • Moreover, the growing geriatric population and Abdominal Aortic Aneurysm incidence in Western countries present a profitable opportunity for the Abdominal Aortic Aneurysm market.

Global Heart Hub launches program to put the spotlight on an 'Invisible Nation' living with ASCVD - the world's #1 killer

Retrieved on: 
Tuesday, October 19, 2021
Lipid, World, Infarction, Conditional sentence, Degenerative disease, Stroke, Rupture, Moyamoya disease, Death, WHO, Artery, Prevalence, Aortic rupture, European Union, Awareness, Human, Novartis, Coronary artery disease, Thrombus, Disease, Bleeding, Program, World Health Organization, Travel, Time, Cardiovascular disease, Atherosclerosis, Atheroma, Patient, Plaque, Partnership, Union, Heart, Cancer, Mortality, Pharmaceutical industry, Medical device

GALWAY, Ireland, Oct. 19, 2021 /PRNewswire/ -- The Global Heart Hub is pleased to launch Invisible Nation, a program aimed to expose and respond to the realities of atherosclerotic cardiovascular disease (ASCVD) – a silent, chronic disease which affects 300 million people across the world. Working with a global network of heart patient organisations and heart patient advocates, and created in partnership with Novartis, Invisible Nation aims to engage with all the stakeholders in cardiovascular diseases.

Key Points: 
  • ASCVD is a leading cause of this global heart disease crisis and we cannot ignore it.
  • This is something close to my heart and I'm proud that Novartis is partnering with Global Heart Hub to enact change.
  • The Global Heart Hub is the first global non-profit organisation established to provide a voice for those affected by or living with cardiovascular disease.
  • After recognizing that the significant prevalence of ASCVD continues to be hidden in plain sight, the Global Heart Hub in collaboration with Novartis decided to create Invisible Nation.

Global Heart Hub launches program to put the spotlight on an 'Invisible Nation' living with ASCVD - the world's #1 killer

Retrieved on: 
Tuesday, October 19, 2021
Lipid, World, Infarction, Conditional sentence, Degenerative disease, Stroke, Rupture, Moyamoya disease, Death, WHO, Artery, Prevalence, Aortic rupture, European Union, Awareness, Human, Novartis, Coronary artery disease, Thrombus, Disease, Bleeding, Program, World Health Organization, Travel, Time, Cardiovascular disease, Atherosclerosis, Atheroma, Patient, Plaque, Partnership, Union, Heart, Cancer, Mortality, Pharmaceutical industry, Medical device

GALWAY, Ireland, Oct. 19, 2021 /PRNewswire/ -- The Global Heart Hub is pleased to launch Invisible Nation, a program aimed to expose and respond to the realities of atherosclerotic cardiovascular disease (ASCVD) – a silent, chronic disease which affects 300 million people across the world. Working with a global network of heart patient organisations and heart patient advocates, and created in partnership with Novartis, Invisible Nation aims to engage with all the stakeholders in cardiovascular diseases.

Key Points: 
  • ASCVD is a leading cause of this global heart disease crisis and we cannot ignore it.
  • This is something close to my heart and I'm proud that Novartis is partnering with Global Heart Hub to enact change.
  • The Global Heart Hub is the first global non-profit organisation established to provide a voice for those affected by or living with cardiovascular disease.
  • After recognizing that the significant prevalence of ASCVD continues to be hidden in plain sight, the Global Heart Hub in collaboration with Novartis decided to create Invisible Nation.